Reuters - Video

Edition: US | UK | IN | CN | JP

video Finance Videos

Reuters Today: Spanish yields seen rising at auction
Reuters Today: Spanish yields seen rising at auction - 06:21
Surprise services boost points to UK recovery
Surprise services boost points to UK recovery - 02:54
Breakingviews: Do as I say, not as I do – German wages
Breakingviews: Do as I say, not as I do – German wages - 05:04
Market Pulse: Spain under fire as investors shun bond sale
Market Pulse: Spain under fire as investors shun bond sale - 03:28
Myanmar's Kyat begins managed float
Myanmar's Kyat begins managed float - 01:59
ASEAN: territorial code of conduct draft by year-end
ASEAN: territorial code of conduct draft by year-end - 01:48
U.S. Morning Call: Stock futures down, JPMorgan to be fined
U.S. Morning Call: Stock futures down, JPMorgan to be fined - 02:08
EMEA Day Ahead:: Thursday
EMEA Day Ahead:: Thursday - 03:13
3XSQ: Customer funds in question; royal return
3XSQ: Customer funds in question; royal return - 05:44
Still cashing in? Hirst retrospective
Still cashing in? Hirst retrospective - 02:32
World's biggest car delivery center
World's biggest car delivery center - 02:41
FACTBOX: Titanic the movie sails again
FACTBOX: Titanic the movie sails again - 02:20

Pfizer's profit plummets

Tuesday, November 01, 2016 - 01:13

The U.S.' largest drugmaker scaled back its profit outlook for the year and said it's stopping development of the cholesterol drug, bococizumab. Fred Katayama reports.

▲ Hide Transcript

▶ View Transcript

A bitter pill for Pfizer investors. The U.S.' largest drugmaker saw quarterly profit plunge 38 percent. Slamming the bottom line: a 39 percent spike in expenses, partly owing to restructuring charges and costs related to the acquisitions of Hospira and Medivation. What's more, Pfizer scaled back its profit outlook for the year. It also said it's abandoning development of its cholesterol drug, bococizumab. Pfizer said the drug became less effective over time in lowering "bad" cholesterol. Two rival drugs had hit the market earlier. Credit Suisse analyst Vamil Divan said, "We view the boco termination as a modest negative." One bright spot: revenue rose, but thanks mostly to the Hospira acquisition. Wall Street is focused on what the company will do now that it has decided not to split itself into two parts - the faster growing newer drugs business led by pain drug Lyrica and its business of established treatments like anti-cholesterol drug Lipitor. Pfizer's shares have fallen nearly 6 percent since it made that decision in September, and they lost further ground at the market open on Tuesday.

Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code

Close

Pfizer's profit plummets

Tuesday, November 01, 2016 - 01:13

Featured Videos

Bladerunners - UK lawnmowers in 12-hour endurance race

Bladerunners - UK lawnmowers in 12-hour endurance race

Drivers donned their suits and climbed into their cockpits at the weekend for a 12-hour endurance race with a difference: they weren't driving rallying cars, but lawnmowers
The highs and lows of Macron's first 100 days

The highs and lows of Macron's first 100 days

French President Emmanuel Macron heads into the summer break faced with falling popularity ratings after tough debates in parliament over labour reform and a public ethics law, a standoff with the military and cuts to housing assistance
The vending machine helping fight against HIV

The vending machine helping fight against HIV

An innovative vending machine for HIV tests being piloted in Britain aims to help in the fight to end the epidemic
London's underground mail rail re-opens after 14 years

London's underground mail rail re-opens after 14 years

A never seen before underground mail network is set to open to the public in London, 14 years after it closed down
Dutch students grow their own biodegradable car

Dutch students grow their own biodegradable car

The first car with a biocomposite body structure has been built by Eindhoven University of Technology students